OKYO Pharma
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Employees
- 3
- Market Cap
- $36.8M
- Introduction
OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.
The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain
Phase 2
Recruiting
- Conditions
- Neuropathic Pain
- Interventions
- Drug: OK-101 0.05%Drug: OK-101 0.1%Drug: Placebo
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Okyo Pharma Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT06637527
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
Phase 2
Completed
- Conditions
- Dry Eye Disease
- Interventions
- Drug: OK-101Drug: Placebo
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Okyo Pharma Ltd
- Target Recruit Count
- 240
- Registration Number
- NCT05759208
- Locations
- 🇺🇸
Total Eye Care, PA, Memphis, Tennessee, United States
🇺🇸Vision Institute, Colorado Springs, Colorado, United States
🇺🇸Andover Eye Associates, Andover, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath